The present study assessed the efficacy and safety of Pregabalin during short-term treatment in adults with neuropathic pain. It explored the PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and Clinical Trials databases for the relevant studies and shortlisted Twelve eligible articles. 

The study looked for Efficacy outcomes like changes in the Daily Pain Rating Scale score (DPRS) and sleep interference score. It evaluated safety based on adverse events, serious adverse events (SAEs), and the incidence of treatment-emergent adverse events (TEAEs).

The observations were as follows-

• The study analyzed 12 articles with 3,169 patients (pregabalin, n = 1,677; placebo, n =1,492).
• It compared the Mean changes in the daily pain rating scale score [MD=-0.65] and daily sleep interference score in patients that received Pregabalin to those that received placebo [MD=-0.81]. 
• Patients receiving Pregabalin had a higher incidence of any TEAE. 
• The pregabalin group showed a higher rate of Serious adverse events (SAEs) than the placebo group, while they showed no marked difference in the incidence rate of discontinuation. 
•  

These comparative results suggest that Pregabalin (150-600 mg/day) significantly reduces the symptoms of neuropathic pain in adults with acceptable safety.

Wu W, Zhang B, Zhao T., et al., efficacy and safety of Pregabalin for chronic neuropathic pain. Neurology Asia. 2020;25(4): p509-517.